<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39359695</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>03</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>04</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2314-7156</ISSN><JournalIssue CitedMedium="Internet"><Volume>2024</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Journal of immunology research</Title><ISOAbbreviation>J Immunol Res</ISOAbbreviation></Journal><ArticleTitle>Studying the Humoral Response against SARS-CoV-2 in Cuban COVID-19 Recovered Patients.</ArticleTitle><Pagination><StartPage>7112940</StartPage><MedlinePgn>7112940</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">7112940</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1155/2024/7112940</ELocationID><Abstract><AbstractText>Understanding the immune response generated by SARS-CoV-2 is critical for assessing efficient therapeutic protocols and gaining insights into the durability of protective immunity. The current work was aimed at studying the specific humoral responses against SARS-CoV-2 in Cuban COVID-19 convalescents. We developed suitable tools and methods based on ELISA methodology, for supporting this evaluation. Here, we describe the development of an ELISA for the quantification of anti-RBD IgG titers in a large number of samples and a similar test in the presence of NH<sub>4</sub>SCN as chaotropic agent for estimating the RBD specific antibody avidity. Additionally, a simple and rapid ELISA based on antibody-mediated blockage of the binding RBD-ACE2 was implemented for detecting, as a surrogate of conventional test, the levels of anti-RBD inhibitory antibodies in convalescent sera. In a cohort of 273 unvaccinated convalescents, we identified higher anti-RBD IgG titer (1 : 1,330, <i>p</i>  &lt; 0.0001) and higher levels of inhibitory antibodies blocking RBD-ACE2 binding (1 : 216, <i>p</i>  &lt; 0.05) among those who had recovered from severe illness. Our results suggest that disease severity, and not demographic features such as age, sex, and skin color, is the main determinant of the magnitude and neutralizing ability of the anti-RBD antibody response. An additional paired longitudinal assessment in 14 symptomatic convalescents revealed a decline in the antiviral antibody response and the persistence of neutralizing antibodies for at least 4 months after the onset of symptoms. Overall, SARS-CoV-2 infection elicits different levels of antibody response according to disease severity that declines over time and can be monitored using our homemade serological assays.</AbstractText><CopyrightInformation>Copyright © 2024 Ivette Orosa Vázquez et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Orosa Vázquez</LastName><ForeName>Ivette</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Center of Molecular Immunology, 15th Avenue and 216 Street, Siboney, Playa, Havana, Cuba.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Díaz</LastName><ForeName>Marianniz</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center of Molecular Immunology, 15th Avenue and 216 Street, Siboney, Playa, Havana, Cuba.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zúñiga Rosales</LastName><ForeName>Yaima</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>National Center of Medical Genetics, 31st Avenue, N°3102 and 146 Street, Cubanacán, Playa, Havana, Cuba.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amada</LastName><ForeName>Klayris</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Julio Trigo Hospital, km 7½ Calzada de Bejucal, Diez de Octubre, Havana, Cuba.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Janoi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Center of Molecular Immunology, 15th Avenue and 216 Street, Siboney, Playa, Havana, Cuba.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Relova Hernández</LastName><ForeName>Ernesto</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Center of Molecular Immunology, 15th Avenue and 216 Street, Siboney, Playa, Havana, Cuba.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tundidor</LastName><ForeName>Yaima</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Center of Molecular Immunology, 15th Avenue and 216 Street, Siboney, Playa, Havana, Cuba.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roblejo Balbuena</LastName><ForeName>Hilda</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>National Center of Medical Genetics, 31st Avenue, N°3102 and 146 Street, Cubanacán, Playa, Havana, Cuba.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Monzón</LastName><ForeName>Giselle</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>National Center of Medical Genetics, 31st Avenue, N°3102 and 146 Street, Cubanacán, Playa, Havana, Cuba.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torres Rives</LastName><ForeName>Bárbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>National Center of Medical Genetics, 31st Avenue, N°3102 and 146 Street, Cubanacán, Playa, Havana, Cuba.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Noa Romero</LastName><ForeName>Enrique</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Research Center of Civil Defense, José de las Lajas, San, Mayabeque, Cuba.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carrillo Valdés</LastName><ForeName>Danay</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Research Center of Civil Defense, José de las Lajas, San, Mayabeque, Cuba.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valdivia Álvarez</LastName><ForeName>Irinia</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Centre for Immunoassays, 134st. And 25, Cubanacán, Playa, Havana, Cuba.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delahanty Fernández</LastName><ForeName>Aurora</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre for Immunoassays, 134st. And 25, Cubanacán, Playa, Havana, Cuba.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Díaz</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Center of Molecular Immunology, 15th Avenue and 216 Street, Siboney, Playa, Havana, Cuba.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Solozabal</LastName><ForeName>Joaquín</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Center of Molecular Immunology, 15th Avenue and 216 Street, Siboney, Playa, Havana, Cuba.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gil</LastName><ForeName>Mileidys</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Julio Trigo Hospital, km 7½ Calzada de Bejucal, Diez de Octubre, Havana, Cuba.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sánchez</LastName><ForeName>Belinda</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Center of Molecular Immunology, 15th Avenue and 216 Street, Siboney, Playa, Havana, Cuba.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rojas</LastName><ForeName>Gertrudis</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Center of Molecular Immunology, 15th Avenue and 216 Street, Siboney, Playa, Havana, Cuba.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marcheco</LastName><ForeName>Beatriz</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>National Center of Medical Genetics, 31st Avenue, N°3102 and 146 Street, Cubanacán, Playa, Havana, Cuba.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carmenate</LastName><ForeName>Tania</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-5366-0035</Identifier><AffiliationInfo><Affiliation>Center of Molecular Immunology, 15th Avenue and 216 Street, Siboney, Playa, Havana, Cuba.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Egypt</Country><MedlineTA>J Immunol Res</MedlineTA><NlmUniqueID>101627166</NlmUniqueID><ISSNLinking>2314-7156</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.17.23</RegistryNumber><NameOfSubstance UI="D000085962">Angiotensin-Converting Enzyme 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.17.23</RegistryNumber><NameOfSubstance UI="C000705307">ACE2 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003462" MajorTopicYN="N" Type="Geographic">Cuba</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="Y">Immunoglobulin G</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056724" MajorTopicYN="Y">Immunity, Humoral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="Y">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="Y">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000085962" MajorTopicYN="N">Angiotensin-Converting Enzyme 2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000915" MajorTopicYN="N">Antibody Affinity</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>7</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>4</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39359695</ArticleId><ArticleId IdType="pmc">PMC11446615</ArticleId><ArticleId IdType="doi">10.1155/2024/7112940</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization. COVID-19 epidemiological update. 2024.  
 https://www.who.int/publications/m/item/covid-19-epidemiological-update-16-february-2024
.</Citation></Reference><Reference><Citation>Cucinotta D., Vanelli M. WHO declares COVID-19 a pandemic. Acta Bio-Medica . 2020;91:157–160. doi: 10.23750/abm.v91i1.9397.</Citation><ArticleIdList><ArticleId IdType="doi">10.23750/abm.v91i1.9397</ArticleId><ArticleId IdType="pmc">PMC7569573</ArticleId><ArticleId IdType="pubmed">32191675</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan W.-J., Ni Z.-Y., Hu Y., et al. Clinical characteristics of coronavirus disease 2019 in China. New England Journal of Medicine . 2020;382(18):1708–1720. doi: 10.1056/NEJMoa2002032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2002032</ArticleId><ArticleId IdType="pmc">PMC7092819</ArticleId><ArticleId IdType="pubmed">32109013</ArticleId></ArticleIdList></Reference><Reference><Citation>Naqvi A. A. T., Fatima K., Mohammad T., et al. Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: structural genomics approach. Biochimica et Biophysica Acta (BBA)—Molecular Basis of Disease . 2020;1866(10) doi: 10.1016/j.bbadis.2020.165878.165878</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2020.165878</ArticleId><ArticleId IdType="pmc">PMC7293463</ArticleId><ArticleId IdType="pubmed">32544429</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q., Zhang Y., Wu L., et al. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell . 2020;181(4):894–904.e9. doi: 10.1016/j.cell.2020.03.045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.03.045</ArticleId><ArticleId IdType="pmc">PMC7144619</ArticleId><ArticleId IdType="pubmed">32275855</ArticleId></ArticleIdList></Reference><Reference><Citation>Rydyznski Moderbacher C., Ramirez S. I., Dan J. M., et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell . 2020;183(4):996–1012.e19. doi: 10.1016/j.cell.2020.09.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.09.038</ArticleId><ArticleId IdType="pmc">PMC7494270</ArticleId><ArticleId IdType="pubmed">33010815</ArticleId></ArticleIdList></Reference><Reference><Citation>McMahan K., Yu J., Mercado N. B., et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature . 2021;590(7847):630–634. doi: 10.1038/s41586-020-03041-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-03041-6</ArticleId><ArticleId IdType="pmc">PMC7906955</ArticleId><ArticleId IdType="pubmed">33276369</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Q., Zhu K., Liu X., et al. The protection of naturally acquired antibodies against subsequent SARS-CoV-2 infection: a systematic review and meta-analysis. Emerging Microbes &amp; Infections . 2022;11(1):793–803. doi: 10.1080/22221751.2022.2046446.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2022.2046446</ArticleId><ArticleId IdType="pmc">PMC8920404</ArticleId><ArticleId IdType="pubmed">35195494</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes C. O., Jette C. A., Abernathy M. E., et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature . 2020;588(7839):682–687. doi: 10.1038/s41586-020-2852-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2852-1</ArticleId><ArticleId IdType="pmc">PMC8092461</ArticleId><ArticleId IdType="pubmed">33045718</ArticleId></ArticleIdList></Reference><Reference><Citation>Smits V. A. J., Hernández-Carralero E., Paz-Cabrera M. D. C., et al. The Nucleocapsid protein triggers the main humoral immune response in COVID-19 patients. Biochemical and Biophysical Research Communications . 2021;543:45–49. doi: 10.1016/j.bbrc.2021.01.073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2021.01.073</ArticleId><ArticleId IdType="pmc">PMC7825866</ArticleId><ArticleId IdType="pubmed">33515911</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohit E., Rostami Z., Vahidi H. A comparative review of immunoassays for COVID-19 detection. Expert Review of Clinical Immunology . 2021;17(6):573–599. doi: 10.1080/1744666X.2021.1908886.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/1744666X.2021.1908886</ArticleId><ArticleId IdType="pubmed">33787412</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Clinical management of COVID-19: interim guidance. 2020.  
 https://www.who.int/publications/i/item/clinical-management-of-covid-19/
</Citation></Reference><Reference><Citation>Mukaka M. M. Statistics corner: a guide to appropriate use of correlation coefficient in medical research. Malawi Medical Journal . 2012;24:69–71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3576830</ArticleId><ArticleId IdType="pubmed">23638278</ArticleId></ArticleIdList></Reference><Reference><Citation>Tai W., He L., Zhang X., et al. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cellular &amp; Molecular Immunology . 2020;17(6):613–620. doi: 10.1038/s41423-020-0400-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-020-0400-4</ArticleId><ArticleId IdType="pmc">PMC7091888</ArticleId><ArticleId IdType="pubmed">32203189</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan C. W., Chia W. N., Qin X., et al. SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein–protein interaction. Nature Biotechnology . 2020;38(9):1073–1078. doi: 10.1038/s41587-020-0631-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-020-0631-z</ArticleId><ArticleId IdType="pubmed">32704169</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L., Wang P., Nair M. S., et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature . 2020;584(7821):450–456. doi: 10.1038/s41586-020-2571-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2571-7</ArticleId><ArticleId IdType="pubmed">32698192</ArticleId></ArticleIdList></Reference><Reference><Citation>Premkumar L., Segovia-Chumbez B., Jadi R., et al. AM. The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Science Immunology . 2020;5(48) doi: 10.1126/sciimmunol.abc8413.eabc8413</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abc8413</ArticleId><ArticleId IdType="pmc">PMC7292505</ArticleId><ArticleId IdType="pubmed">32527802</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodda L. B., Netland J., Shehata L., et al. Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. Cell . 2021;184(1):169–183.e17. doi: 10.1016/j.cell.2020.11.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.11.029</ArticleId><ArticleId IdType="pmc">PMC7682481</ArticleId><ArticleId IdType="pubmed">33296701</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson E. M., Goodwin E. C., Verma A., et al. Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection. Cell . 2021;184(7):1858–1864.e10. doi: 10.1016/j.cell.2021.02.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.02.010</ArticleId><ArticleId IdType="pmc">PMC7871851</ArticleId><ArticleId IdType="pubmed">33631096</ArticleId></ArticleIdList></Reference><Reference><Citation>Arias-Arias J. L., Molina-Castro S. E., Monturiol-Gross L., Lomonte B., Corrales-Aguilar E. Stable production of recombinant SARS-CoV-2 receptor-binding domain in mammalian cells with co-expression of a fluorescent reporter and its validation as antigenic target for COVID-19 serology testing. Biotechnology Reports . 2023;37 doi: 10.1016/j.btre.2022.e00780.e00780</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.btre.2022.e00780</ArticleId><ArticleId IdType="pmc">PMC9805376</ArticleId><ArticleId IdType="pubmed">36619904</ArticleId></ArticleIdList></Reference><Reference><Citation>Benabdessalem C., Hamouda W. B., Marzouki S., et al. Development and comparative evaluation of SARS-CoV-2 S-RBD and N based ELISA tests in various African endemic settings. Diagnostic Microbiology and Infectious Disease . 2023;105(4) doi: 10.1016/j.diagmicrobio.2023.115903.115903</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diagmicrobio.2023.115903</ArticleId><ArticleId IdType="pmc">PMC9867841</ArticleId><ArticleId IdType="pubmed">36805620</ArticleId></ArticleIdList></Reference><Reference><Citation>Guarino C., Larson E., Babasyan S., et al. Development of a quantitative COVID-19 multiplex assay and its use for serological surveillance in a low SARS-CoV-2 incidence community. PLOS ONE . 2022;17(1) doi: 10.1371/journal.pone.0262868.e0262868</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0262868</ArticleId><ArticleId IdType="pmc">PMC8782306</ArticleId><ArticleId IdType="pubmed">35061843</ArticleId></ArticleIdList></Reference><Reference><Citation>Korn J., Schäckermann D., Kirmann T., et al. Baculovirus-free insect cell expression system for high yield antibody and antigen production. Scientific Reports . 2020;10(1) doi: 10.1038/s41598-020-78425-9.21393</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-78425-9</ArticleId><ArticleId IdType="pmc">PMC7721901</ArticleId><ArticleId IdType="pubmed">33288836</ArticleId></ArticleIdList></Reference><Reference><Citation>Villafañe L., Vaulet L. G., Viere F. M., et al. Development and evaluation of a low cost IgG ELISA test based in RBD protein for COVID-19. Journal of Immunological Methods . 2022;500 doi: 10.1016/j.jim.2021.113182.113182</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jim.2021.113182</ArticleId><ArticleId IdType="pmc">PMC8574101</ArticleId><ArticleId IdType="pubmed">34762914</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemos Perez G., Chavez Valdes S., Gonzalez Formental H., et al. Elevated antibody titers in abdala vaccinees evaluated by Elecsys® AntiSARS-Cov-2 S highly correlate with UMELISA SARS-Cov-2 ANTI RBD, ACE-2 binding inhibition and viral neutralization assays. Journal of Biotechnology and Biomedicine . 2022;5:151–157.</Citation></Reference><Reference><Citation>Toledo-Romani M. E., García-Carmenate M., Verdecia-Sánchez L., et al. Safety and immunogenicity of anti-SARS-CoV-2 heterologous scheme with SOBERANA 02 and SOBERANA Plus vaccines: phase IIb clinical trial in adults. Med . 2022;11:760–773.e5. doi: 10.1016/j.medj.2022.08.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medj.2022.08.001</ArticleId><ArticleId IdType="pmc">PMC9359498</ArticleId><ArticleId IdType="pubmed">35998623</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X., Pan Z., Yue S., et al. Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19. Signal Transduction and Targeted Therapy . 2020;5(1) doi: 10.1038/s41392-020-00301-9.180</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-020-00301-9</ArticleId><ArticleId IdType="pmc">PMC7464057</ArticleId><ArticleId IdType="pubmed">32879307</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng S., Fan J., Yu F., et al. Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January–March 2020: retrospective cohort study. BMJ . 2020;369 doi: 10.1136/bmj.m1443.m1443</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m1443</ArticleId><ArticleId IdType="pmc">PMC7190077</ArticleId><ArticleId IdType="pubmed">32317267</ArticleId></ArticleIdList></Reference><Reference><Citation>Shenoy S. SARS-CoV-2 (COVID-19), viral load and clinical outcomes; lessons learned 1 year into the pandemic: a systematic review. World Journal of Critical Care Medicine . 2021;10(4):132–150. doi: 10.5492/wjccm.v10.i4.132.</Citation><ArticleIdList><ArticleId IdType="doi">10.5492/wjccm.v10.i4.132</ArticleId><ArticleId IdType="pmc">PMC8291003</ArticleId><ArticleId IdType="pubmed">34316448</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodruff M. C., Ramonell R. P., Nguyen D. C., et al. Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19. Nature Immunology . 2020;21(12):1506–1516. doi: 10.1038/s41590-020-00814-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-020-00814-z</ArticleId><ArticleId IdType="pmc">PMC7739702</ArticleId><ArticleId IdType="pubmed">33028979</ArticleId></ArticleIdList></Reference><Reference><Citation>Junqueira C., Crespo Â., Ranjbar S., et al. FcγR-mediated SARS-CoV-2 infection of monocytes activates inflammation. Nature . 2022;606(7914):576–584. doi: 10.1038/s41586-022-04702-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04702-4</ArticleId><ArticleId IdType="pmc">PMC10071495</ArticleId><ArticleId IdType="pubmed">35385861</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoury D. S., Cromer D., Reynaldi A., et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nature Medicine . 2021;27(7):1205–1211. doi: 10.1038/s41591-021-01377-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01377-8</ArticleId><ArticleId IdType="pubmed">34002089</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho F. K., Petermann-Rocha F., Gray S. R., et al. Is older age associated with COVID-19 mortality in the absence of other risk factors? General population cohort study of 470,034 participants. PLOS ONE . 2020;15(11) doi: 10.1371/journal.pone.0241824.e0241824</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0241824</ArticleId><ArticleId IdType="pmc">PMC7644030</ArticleId><ArticleId IdType="pubmed">33152008</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu F., Liu M., Wang A., et al. Evaluating the Association of Clinical Characteristics with Neutralizing Antibody Levels in Patients who have Recovered from Mild COVID-19 . Vol. 180. Shanghai, China: JAMA Internal Medicine; 2020. pp. 1356–1362.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2020.5576</ArticleId><ArticleId IdType="pmc">PMC9377417</ArticleId><ArticleId IdType="pubmed">32808970</ArticleId></ArticleIdList></Reference><Reference><Citation>Pradenas E., Trinité B., Urrea V. D., et al. Clinical course impacts early kinetics, magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection. Cell Reports Medicine . 2022;3(2) doi: 10.1016/j.xcrm.2022.100523.100523</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2022.100523</ArticleId><ArticleId IdType="pmc">PMC8784437</ArticleId><ArticleId IdType="pubmed">35233547</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner J. S., Kim W., Kalaidina E., et al. SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans. Nature . 2021;595(7867):421–425. doi: 10.1038/s41586-021-03647-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03647-4</ArticleId><ArticleId IdType="pubmed">34030176</ArticleId></ArticleIdList></Reference><Reference><Citation>Sokal A., Chappert P., Barba-Spaeth G., et al. Maturation and persistence of the anti-SARS-CoV-2 memory B cell response. Cell . 2021;184(5):1201–1213.e14. doi: 10.1016/j.cell.2021.01.050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.01.050</ArticleId><ArticleId IdType="pmc">PMC7994111</ArticleId><ArticleId IdType="pubmed">33571429</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>